Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study

Abstract

IntroductionThere are no disease-modifying treatments for Parkinson’s disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA in PD at 30 mg/kg, confirm the target engagement of UDCA, apply a novel motion sensor-based approach to quantify disease progression objectively, and estimate the mean effect size and its variance on the change in motor severity.Methods and analysisThis is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30 mg/kg in 30 participants with early PD. Treatment duration is 48 weeks, followed by an 8-week washout phase. Randomisation is 2:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48 and 56. The primary outcome is safety and tolerability. Secondary outcomes will compare the change between baseline and week 48 using the following three approaches: the Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part 3 in the practically defined ‘OFF’ medication state; confirmation of target engagement, applying 31Phosphorus MR Spectroscopy to assess the levels of ATP and relevant metabolites in the brain; and objective quantification of motor impairment, using a validated, motion sensor-based approach. The primary outcome will be reported using descriptive statistics and comparisons between treatment groups. For each secondary outcome, the change from baseline will be summarised within treatment groups using summary statistics and appropriate statistical tests assessing for significant differences. All outcomes will use an intention-to-treat analysis population.Ethics and disseminationThis trial has been approved by the East of England – Cambridgeshire and Hertfordshire Research Ethics committee. Results will be disseminated in peer-reviewed journals, presentations at scientific meetings and to patients in a lay-summary format.Trial registration numberNCT03840005.

Striatal synaptic bioenergetic and autophagic decline in premotor experimental parkinsonism

“…Modulation of some of these proteins related to the mitochondrial compartment aiming to restore bioenergetics to preserve synaptic function could be a potential therapeutic strategy. In this regard, recent studies stimulating the clearance of damaged mitochondria in patients with Parkinson’s disease 53 , 54 and other neurodegenerative diseases, 55 as well as in animal models of parkinsonism or fibroblasts from idiopathic Parkinson’s disease patients have shown promising results. 54 , 56 Additionally, other small-molecules enhancing mitophagy have been described as potential therapeutic targets in parkinsonian models.…”

The Genetics of Parkinson’s Disease and Implications for Clinical Practice

“…Phase II studies are registered for the molecules ANVS-401 (NCT04524351) and ENT-01 (NCT03781791). However, nilotinib, which is used in chronic myeloid leukaemia and has been shown to accelerate α-synuclein degradation, showed no efficacy [ 185 ].…”

The Role of Bile Acids in the Human Body and in the Development of Diseases

“…A placebo-controlled phase II study is currently underway to examine the efficacy of UDCA at a dose of 30 mg/kg per day in the treatment of parkinsonism. The theoretical basis for the use of BAs in this study is its potentially beneficial effect on mitochondrial function; it involves performing a functional magnetic resonance imaging of the brain with the isotope of phosphorus 31P to assess the state of ATP metabolism [ 64 ].…”